Europe — EMA

Ondansetrom Eignapharma (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Eignapharma, is a 5-HT3 receptor antagonist presented as a unknown/unknown for oral use.

Ondansetron

Request sourcing

Pack/s

What is Ondansetron?

Ondansetron, the active ingredient in Ondansetrom Eignapharma, is a 5-HT3 receptor antagonist presented as a unknown/unknown for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetrom Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

What is Ondansetron used for?

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: Reduces the risk of vomiting and helps maintain treatment continuity. - Post‑operative post‑operative vomiting: Prevents the on the the ... - Radiotherapy induced ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... "

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →